Last updated on June 2016

A Multicenter Trial of the Efficacy and Safety of Diclegis for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Morning Sickness
  • Age: Between 12 - 17 Years
  • Gender: Female
  • Other:
    The participant is a pregnant female between the following ages: at least 12 years on
    the day of recruitment (ie, Day 1) and not yet 18 years on the last day of the study
    (ie, Day 15).
    The participant must provide written informed consent and/or assent to participate in
    the study, and agrees that she will follow dosing instructions and complete all
    required study visits.
    The participant's entry ultrasound indicates a viable pregnancy and confirms
    gestational age of the fetus is 7-15 weeks + 0 days at the anticipated time of the
    first dose of study drug provided that her NVP symptoms began If an ultrasound was performed within 4 weeks of the study entry visit, and results
    can be obtained, an additional ultrasound is not necessary.
    The participant is suffering from NVP and has a PUQE score ≥6.
    The participant has not responded to conservative management consisting of
    dietary/lifestyle advice according to the 2004 ACOG Practice Bulletin.
    The participant agrees, if on a multivitamin, to continue on her current dose of
    multivitamin for the duration of the trial.
    The participant does not plan termination of the pregnancy.
    On the basis of medical history, physical examination and screening laboratory tests,
    the participant is judged to be in good health.
    The participant must be able to swallow the study drug whole (ie, without splitting,
    crushing, or chewing the tablets).

You may not be eligible for this study if the following are true:

  • The investigator confirms the participant's nausea and vomiting is of etiology other
    than NVP.
    The participant has gestational trophoblastic disease or multifetal gestation.
    The participant has a condition for which antihistamines, in the opinion of the
    investigator, are contraindicated (eg, epilepsy, alcoholism, glaucoma, chronic lung
    disease, urinary retention, and heart block).
    The participant has a known hypersensitivity to doxylamine succinate other
    ethanolamine derivative antihistamines, pyridoxine hydrochloride, or any inactive
    ingredient in the Diclegis or placebo formulation.
    The participant is taking a monoamine oxidase inhibitor.
    The participant has used antihistamines, anticholinergics, dopamine antagonists,
    erotonin antagonists, ginger, or anti-emetic therapy (including acupressure,
    acupuncture, homeopathic remedies, medical hypnosis, and relief bands) to treat NVP
    in the previous 48 hours or plans to do so during the study.
    The participant is using drugs that have anticholinergic activity (eg, tricyclic
    The participant is taking multivitamins containing more than 10 mg of vitamin B6 or
    plans to do so during the study.
    The participant is taking supplementary vitamin B6 in addition to any multivitamin
    preparation or plans to do so during the study (e.g, total vitamin B6 greater than 10
    The participant is currently drinking any amount of alcohol.
    The participant has any condition that might interfere with the conduct of the study,
    in the opinion of the investigator. For example, Diclegis® should be used with
    caution in females with asthma, increased intraocular pressure, narrow angle
    glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction and urinary bladder-neck
    The participant is likely to be unable to comply with study procedures because of
    inadequate cognitive or language skills.
    The participant has received an investigational drug within 30 days before enrollment
    in this study or is scheduled to receive an investigational drug during the course of
    this study.
    The participant is currently breastfeeding.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.